Imunon Inc (IMNN) is not a strong buy at the moment. The stock lacks positive momentum, has weak financial performance, no significant trading trends, and no recent news or catalysts to drive growth. For a beginner investor with a long-term strategy, this stock does not present a compelling investment opportunity right now.

Technical Analysis

The MACD is slightly positive, indicating weak bullish momentum, but the RSI is neutral at 36.314. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a downward trend. The stock is trading below its pivot point of 3.284, with key support at 3.012.

Positive Catalysts

No positive catalysts identified. No recent news or significant trading trends.

Neutral/Negative Catalysts

Weak financial performance in Q3 2025, with a YoY net income drop of -29.23% and EPS decline of -76.94%. No insider or hedge fund activity, and no recent congress trading data.

Financial Performance

In Q3 2025, revenue remained at 0 with no growth. Net income dropped to -$3,429,124, down -29.23% YoY. EPS fell significantly by -76.94% YoY to -1.01. Gross margin remained at 0, showing no improvement.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

1 Analyst Rating

Wall Street analysts forecast IMNN stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.250

Low

Averages

High

Current: 3.250

Low

Averages

High

D. Boral Capital

Jason Kolbert

Buy

Hold

downgrade

AI Analysis

2025-05-19

Reason

D. Boral Capital

Jason Kolbert

Price Target

AI Analysis

2025-05-19

downgrade

Buy

Hold

Reason

D. Boral Capital analyst Jason Kolbert downgraded Imunon to Hold from Buy without a price target. The company announced "encouraging" six-month follow-up data from its Phase 1 COVID-19 vaccine study, but the update is immaterial to the investment thesis, which remains centered on Imunon's ovarian cancer program, the analyst tells investors in a research note. The firm says the "more pressing development" is the recently filed prospectus for potentially dilutive financing that could create a significant number of new shares. Given the scale of dilution and uncertainty around shareholder approval, D. Boral downgraded the stock.

Boral Capital

D. Boral

Buy

downgrade

$29 -> $17

2025-05-13

Reason

Boral Capital

D. Boral

Price Target

$29 -> $17

2025-05-13

downgrade

Buy

Reason

D. Boral Capital lowered the firm's price target on Imunon to $17 from $29 and keeps a Buy rating on the shares. The firm now anticipates a series of dilutive financings that are likely to exceed its prior expectations. Imunon has entered a pivotal new phase in its development with the initiation of the Phase 3 OVATION 3 trial evaluating IMNN-001, its lead DNA-based immunotherapy candidate, in newly diagnosed advanced ovarian cancer, the analyst tells investors in a research note. With only $2.9M in cash as of March 31, the company's "financial position remains precarious," contends D. Boral.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMNN

Unlock Now

IMNN Should I Buy

IMNN Should I Buy

Should You Buy Imunon Inc (IMNN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch